Close Menu

neurological disorders

NEW YORK (GenomeWeb News) – Indiana University has launched a new $150 million, five-year effort that will use genetics and personalized medicine, among other approaches, to develop new capabilities and translational research projects focused on cancer, neuroscience, and cardiovascular medicine,

Janssen and J&J's Ortho-Clinical Diagnostics group have worldwide exclusive rights to develop and commercialize assays on the Biocartis platform in the fields of neurological disease and certain viral infectious diseases.

A new NINDS and NIMH grant program will provide up to $5 million in grants to develop scalable assays for analysis of molecular and cellular events in neurons related to brain functioning.

NINDS and Coriell Institute will continue to work together to expand a biorepository of clinical data and human samples that will facilitate genetic research into neurological conditions.

Although iZumi does not have a license to Kyoto iPSC patents, the collaboration builds upon other seminal iPSC IP it recently licensed from Bayer. The Kyoto deal may also help the company better define iZumi's stake in what is shaping up to be a complicated IP landscape surrounding the technology.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

NHLBI plans to launch next month the prospectively designed, randomized-controlled study, called Clarification of Optimal Anticoagulation through Genetics trial, which will follow 1,200 patients to see if PGx-guided dosing is clinically useful.

Pages

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.